India biotech funding gaps noted
A recent piece argued that India remains a manufacturing powerhouse but lacks predictable deep‑science funding, with policy friction and capital gaps slowing long-term biotech innovation. The article framed uneven funding and short-term opportunities as a structural challenge for researchers and startups. (indiatoday.in)
India’s biotechnology sector is growing fast, but founders and investors say India still lacks the steady long-term capital needed to keep deep-science startups at home. (indiatoday.in) India Today reported on April 11 that an investor’s post described a cancer-vaccine startup in India, led by a Yale-trained founder and more than 100 scientists, weighing an overseas legal shift after struggling to raise money and clear regulations. The article said biotech investors often balk at the 7-to-10-year timelines common in drug and vaccine development. (indiatoday.in) The pressure comes as India’s bioeconomy keeps expanding on paper. The India BioEconomy Report 2026 put the sector above $195 billion and counted more than 11,850 biotechnology startups. (birac.nic.in) Biotechnology is the business of turning living cells into products such as vaccines, diagnostics, seeds, enzymes, and industrial materials. The bottleneck is that many of those products need years of lab work, animal studies, human trials, and regulatory review before they earn revenue. (thehindubusinessline.com) That long cycle has pushed the funding debate into public view in 2026. Biocon Executive Chairperson Kiran Mazumdar-Shaw said on April 7 that weak venture funding, regulatory bottlenecks, and limited exit routes are pushing high-value biotech innovation out of India. (thehindubusinessline.com) New Delhi has started to respond with policy changes. In February, India extended deep-tech startup status to 20 years and raised the revenue ceiling for related tax, grant, and regulatory benefits to ₹3 billion from ₹1 billion, a change meant to fit longer research timelines in fields including biotechnology. (techcrunch.com) The government has also added new pools of public capital. On February 14, the Union Cabinet approved Startup India Fund of Funds 2.0 with a ₹10,000 crore corpus for deep tech, tech-driven manufacturing, and early-growth startups. (pib.gov.in) That same week, the government launched the first national call under a ₹2,000 crore Biotechnology Industry Research Assistance Council Research, Development and Innovation fund. The fund is set to back projects from Technology Readiness Level 4 to 9, meaning work that has moved beyond basic science toward usable products and scaled deployment. (theweek.in) Officials and industry leaders are describing the same market from different angles. Government reports point to rapid growth in startups and sector value, while founders and executives keep arguing that clinical-stage companies still face the hardest stretch, when costs rise before sales begin. (birac.nic.in) (thehindubusinessline.com) The next test is whether those February policy changes and new funds produce follow-on financing for companies that stay in India through trials, approvals, and commercialization. That is the gap the April 11 debate put in front of the country’s biotech sector. (techcrunch.com) (indiatoday.in)
